Kolexia
Perrin Christophe Oncologie médicale
Perrin Christophe
Oncologie médicale
Centre Eugène Marquis
Rennes, France
94 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Sarcomes Métastase tumorale Carcinomes Tumeurs osseuses Néphrocarcinome Sarcome d'Ewing Chondrosarcome Tumeurs du cerveau

Collaborateurs

Voir plus
Bertucci Francois
Bertucci Francois
Centre Paoli-Calmettes, Marseille, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Bompas Emmanuelle
Bompas Emmanuelle
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
Lilly
2 collaboration(s)
Dernière en 2022
Amgen
2 collaboration(s)
Dernière en 2023
Boehringer Ingelheim
2 collaboration(s)
Dernière en 2023
Daiichi Sankyo
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Molecular oncology   29 janvier 2024
Improved nationwide survival of sarcoma patients with a network of reference centers.
Annals of oncology : official journal of the European Society for Medical Oncology   19 janvier 2024
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.
European journal of cancer (Oxford, England : 1990)   23 novembre 2023
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1): A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)
Essai Clinique (Daiichi Sankyo)   10 novembre 2023
REGOBONE: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Essai Clinique (Unicancer)   06 novembre 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
British journal of cancer   01 novembre 2023
1927P Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten): Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
Essai Clinique (Centre Léon-Bérard)   31 août 2023
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.
European journal of cancer (Oxford, England : 1990)   29 juillet 2023
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
ESMO open   06 juin 2023